AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 18850558
Drug: Brimonidine 0.2%
RxNorm normalized name: BRIMONIDINE 0.2%/TIMOLOL 0.5% OPH SOLN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brimonidine 0.2% and timolol 0.5% (fixed combination)
Trial: 18850558
Drug: Dorzolamide 2%
RxNorm normalized name: Brimonidine Tartrate 0.1%, Dorzolamide 2% Ophthalmic drops, solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dorzolamide 2% and timolol 0.5% (fixed combination)
Trial: 18850558
Drug: Brimonidine 0.2%
RxNorm normalized name: BRIMONIDINE 0.2%/TIMOLOL 0.5% OPH SOLN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brimonidine 0.2% (adjunctive therapy)
Trial: 18850558
Drug: Dorzolamide 2%
RxNorm normalized name: Brimonidine Tartrate 0.1%, Dorzolamide 2% Ophthalmic drops, solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dorzolamide 2% (adjunctive therapy)
Trial: 18850558
Drug: Brimonidine/timolol (fixed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brimonidine/timolol (fixed combination)
Trial: 11232987
Drug: Aspirin, ticlopidine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin, ticlopidine, and further intravenous heparin infusion for 48 hours following primary coronary stenting (Group 1)
Trial: 11232987
Drug: Aspirin and
RxNorm normalized name: Aspirin and Caffeine Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin and ticlopidine without further heparin therapy following primary coronary stenting (Group 2)
Trial: 6368610
Drug: Ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic acid 250 mg q.i.d.
Trial: 26110891
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of 6% v/v EtOH (alcohol)
Trial: 21480681
Drug: Static and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Static and dynamic risk factors (alcohol dependence severity, treatment history, marital status, psychiatric symptoms, negative affect, craving, stress)
Trial: 21480681
Drug: Static risk
RxNorm normalized name: Hep B, adolescent/high risk infant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Static risk factors (alcohol dependence severity, treatment history, marital status, psychiatric symptoms)
Trial: 19588684
Drug: Continuous thoracic
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous thoracic epidural administration of bupivacaine with midazolam (group B)
Trial: 19588684
Drug: Continuous thoracic
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous thoracic epidural administration of bupivacaine (group A)
Trial: 12798539
Drug: Oral misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral misoprostol 400 microg every 3 hours (group 2)
Trial: 12798539
Drug: Loading dose
RxNorm normalized name: NUZYRA 7-Day Oral Pack including loading dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loading dose of vaginal misoprostol 600 microg followed by oral misoprostol 200 microg every 3 hours (group 3)
Trial: 10847283
Drug: Vicoprofen (ibuprofen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vicoprofen (ibuprofen 200 mg/hydrocodone 7.5 mg)
Trial: 10847283
Drug: Acetaminophen with
RxNorm normalized name: acetaminophen with codeine ORAL ELIXIR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen with codeine (acetaminophen 300 mg/codeine 30 mg)
Trial: 1728377
Drug: Low doses
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low doses of mitomycin C (5 mg/m2, intravenously) every 6 weeks
Trial: 1728377
Drug: Standard doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard doses of mitomycin C (20 mg/m2, intravenously) every 6 weeks
Trial: 20194878
Drug: Ticagrelor (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticagrelor (180 mg/90 mg twice daily)
Trial: 20194878
Drug: Clopidogrel (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (600 mg/75 mg once daily)
Trial: 25660925
Drug: Ticagrelor therapy
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor therapy
Trial: 17095943
Drug: Nutrient infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nutrient infusion of Ensure at 1 kcal/min
Trial: 17095943
Drug: Nutrient infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nutrient infusion of Ensure at 2 kcal/min
Trial: 17095943
Drug: Nutrient infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nutrient infusion in patients with feed intolerance
Trial: 17095943
Drug: Nutrient infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nutrient infusion in patients with impaired renal function
Trial: 9926181
Drug: i.v. ketoprofen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. ketoprofen (1 mg kg-1 followed by an infusion of 1 mg kg-1 over 2 h)
Trial: 1693062
Drug: rG-CSF administered
RxNorm normalized name: rGM-CSF
DrugBank: Sargramostim (DB00020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: rG-CSF administered intravenously at a dose of 100 micrograms/m2
Trial: 1693062
Drug: rG-CSF administered
RxNorm normalized name: rGM-CSF
DrugBank: Sargramostim (DB00020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: rG-CSF administered subcutaneously at a dose of 75 micrograms
Trial: 1693062
Drug: rG-CSF administered
RxNorm normalized name: rGM-CSF
DrugBank: Sargramostim (DB00020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: rG-CSF administered subcutaneously at a dose of 100 micrograms/m2
Trial: 1693062
Drug: rG-CSF administered
RxNorm normalized name: rGM-CSF
DrugBank: Sargramostim (DB00020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: rG-CSF administered subcutaneously at a dose of 125 micrograms
Trial: 7387806
Drug: Incremental administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Incremental administration of thiopentone (50‐mg increments every 15 s)
Trial: 7387806
Drug: Bolus administration
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus administration of thiopentone (4‐mg kg‐1)
Trial: 31875276
Drug: Subcutaneous pasireotide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous pasireotide 600-μg twice daily
Trial: 31875276
Drug: Subcutaneous pasireotide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous pasireotide 900-μg twice daily
Trial: 31125538
Drug: Anterior technique
RxNorm normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anterior technique with 2.7 mL of anesthetic
Trial: 31125538
Drug: Anterior technique
RxNorm normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anterior technique with 1.8 mL of anesthetic
Trial: 31125538
Drug: Conventional IANB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional IANB with 1.8 mL of anesthetic
Trial: 31125538
Drug: Conventional IANB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional IANB with 2.7 mL of anesthetic
Trial: 27173671
Drug: Front treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Front treatment (targeted product placed in the front)
Trial: 27173671
Drug: Back treatment
RxNorm normalized name: Salicylic Acid 4.72 mL in 118 mL TOPICAL SPRAY [MARK. BACK UP PLAN ANTI-ACNE BACK TREATMENT]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Back treatment (targeted product placed in the back)
Trial: 27173671
Drug: Unboxed treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unboxed treatment (targeted product presented unboxed)
Trial: 23981052
Drug: Early follicular
RxNorm normalized name: Follicular hormone
DrugBank: Estrone (DB00655)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early follicular phase (low hormone levels)
Trial: 23981052
Drug: Luteal phase
RxNorm normalized name: Nuphar lutea leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Luteal phase (high hormone levels)
Trial: 17901096
Drug: Daily clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily clinical assessment, prevalence surveys, randomized controlled trial settings
Trial: 12447512
Drug: Fluconazole 100
RxNorm normalized name: fluconazole 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole 100 mg daily
Trial: 10512345
Drug: Clotrimazole 1%
RxNorm normalized name: CLOTRIMAZOLE 1% LOTION
DrugBank: Clotrimazole (DB00257)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clotrimazole 1% cream applied twice daily for 3 weeks
Trial: 10512345
Drug: Fluconazole 200
RxNorm normalized name: fluconazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole 200 mg once weekly for 3 weeks
Trial: 8835618
Drug: Chlorthalidone 23
RxNorm normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorthalidone 23 mg
Trial: 8835618
Drug: Chlorthalidone (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorthalidone (both doses)
Trial: 6892984
Drug: MOPP chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MOPP chemotherapy (mechlorethamine, vincristine, procarbazine, and prednisone)
Trial: 23666915
Drug: Ipilimumab at
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ipilimumab at 0.3 mg/kg
Trial: 23666915
Drug: Ipilimumab at
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ipilimumab at 3 mg/kg
Trial: 23666915
Drug: Ipilimumab at
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ipilimumab at 10 mg/kg
Trial: 23666915
Drug: Ipilimumab at
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ipilimumab at 10 mg/kg (treatment-naïve patients)
Trial: 23666915
Drug: Ipilimumab at
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ipilimumab at 10 mg/kg (retreatment upon disease progression)
Trial: 17034372
Drug: Eflornithine cream
RxNorm normalized name: eflornithine Topical Cream
DrugBank: Eflornithine (DB06243)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eflornithine cream
Trial: 17034372
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (Eflornithine + laser)
Trial: 9989685
Drug: Red yeast
RxNorm normalized name: red yeast
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red yeast rice (2.4 g/d)
Trial: 119975
Drug: Local nitrofurantoin
RxNorm normalized name: Nitrofurantoin
DrugBank: Nitrofurantoin (DB00698)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Local nitrofurantoin treatment
Trial: 119975
Drug: Local treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local treatment of the vagina
Trial: 25675664
Drug: Levobupivacaine infiltration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levobupivacaine infiltration (5 ml, 50 mg/10 ml)
Trial: 22436595
Drug: Psycho-educational and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psycho-educational and cognitive behavioural stabilizing group treatment (experimental treatment; EXP) added to treatment as usual (TAU)
Trial: 15866397
Drug: Ibuprofen 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 5% cream
Trial: 11935040
Drug: Presence of
RxNorm normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Presence of anti-CMV antibodies in IC
Trial: 7872228
Drug: 6 g
RxNorm normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 g n-3 FAs/d for 6 weeks followed by 3 g/d for 12 weeks
Trial: 29677641
Drug: UFT (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UFT (oral tegafur-uracil) at 500-600 mg/day for 5 days followed by 2-day rest for 1 year
Trial: 29677641
Drug: UFT (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UFT (oral tegafur-uracil)
Trial: 24002280
Drug: Micronutrient powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronutrient powder (MNP) with iron (12.5 mg/d of iron)
Trial: 19026262
Drug: Panic‐Focused Psychodynamic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Panic‐Focused Psychodynamic Therapy (PFPP)
Trial: 19026262
Drug: Applied Relaxation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Applied Relaxation Therapy (ART)
Trial: 7955819
Drug: Isoproterenol infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoproterenol infusion (0.0025 to 0.01 micrograms/kg/min) with ganglionic blockade (trimethaphan) in young subjects
Trial: 7955819
Drug: Isoproterenol infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoproterenol infusion (0.005 to 0.03 micrograms/kg/min) without ganglionic blockade
Trial: 31764068
Drug: Oral placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo arm of VOICE trial
Trial: 8237930
Drug: Ethanol injection
RxNorm normalized name: ethanol Injection
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ethanol injection
Trial: 24954607
Drug: Sodium tetradecyl
RxNorm normalized name: Sodium tetradecylsulfate
DrugBank: Sodium tetradecyl sulfate (DB00464)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium tetradecyl sulfate (STS) injection
Trial: 22252206
Drug: Pentavalent human-bovine
RxNorm normalized name: human-bovine reassortant rotavirus strain G1 vaccine / human-bovine reassortant rotavirus strain G2 vaccine / human-bovine reassortant rotavirus strain G3 vaccine / human-bovine reassortant rotavirus strain G4 vaccine / human-bovine reassortant rotavirus strain P1A[8] vaccine Oral Suspension [RotaTeq]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentavalent human-bovine reassortant rotavirus vaccine (PRV)
Trial: 18300064
Drug: Sequential presentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential presentation of risks
Trial: 15911729
Drug: Bezafibrate (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bezafibrate (400 mg once a day)
Trial: 12896934
Drug: Active treatment:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment: two injections of enzyme potentiated desensitisation, each comprising 200 Fishman units of beta glucuronidase, 50 pg 1,3‐cyclohexanediol, 50 ng protamine sulphate, and a mixed inhaled allergen extract in a total volume of 0.05 ml of buffered saline.
Trial: 12896934
Drug: Placebo: two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo: two injections of 0.05 ml buffered saline solution.
Trial: 1832920
Drug: Mivacurium 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mivacurium 0.15 mg kg-1
Trial: 1832920
Drug: Mivacurium 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mivacurium 0.2 mg kg-1
Trial: 1832920
Drug: Mivacurium 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mivacurium 0.2 mg kg-1 over 30 s
Trial: 1832920
Drug: Mivacurium infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mivacurium infusion at 8-10 micrograms kg-1 min-1
Trial: 1832920
Drug: Neostigmine 0.04
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine 0.04 mg kg-1
Trial: 1832920
Drug: Edrophonium 0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edrophonium 0.75 mg kg-1
Trial: 27864024
Drug: SQ HDM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SQ HDM SLIT tablet (10,000 JAU)
Trial: 27864024
Drug: SQ HDM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SQ HDM SLIT tablet (20,000 JAU)
Trial: 27864024
Drug: SQ HDM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SQ HDM SLIT tablet
Trial: 26850270
Drug: Oral tenofovir
RxNorm normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral tenofovir (TFV)
Trial: 26850270
Drug: Oral group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral group correlates
Trial: 25148718
Drug: I-Gel™
FDA approved: no
EMA approved: no
PMDA approved: no
Description: I-Gel™
Trial: 20647390
Drug: Oral lactoferrin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral lactoferrin (200 mg/day)
Trial: 20647390
Drug: i.v. iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. iron (125 mg weekly)
Trial: 17452390
Drug: Community pharmacist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community pharmacist intervention (two home visits within two to eight weeks of discharge, drug review, symptom self-management, and lifestyle advice)
Trial: 15476202
Drug: Folinic acid
RxNorm normalized name: Folinic acid
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Folinic acid supplementation during MTX therapy
Trial: 15476202
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid supplementation during MTX therapy
Trial: 9505927
Drug: Metoprolol 50
RxNorm normalized name: metoprolol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol 50 mg twice daily (n = 19)
Trial: 9505927
Drug: Celiprolol 200
RxNorm normalized name: celiprolol 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celiprolol 200 mg daily (n = 21)
Trial: 7838448
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of sodium nitroprusside in experimental infarction
Trial: 31820546
Drug: Standard heart
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard heart failure care (triple therapy)
Trial: 26047615
Drug: Eurythmy therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eurythmy therapy A (EYT-A)
Trial: 26047615
Drug: Eurythmy therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eurythmy therapy B (EYT-B)
Trial: 21159892
Drug: lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lansoprazole 30 mg/day
Trial: 2653119
Drug: Cervical epidural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cervical epidural anesthesia (CEA) with 15 ml of 0.375% bupivacaine and 150 micrograms fentanyl.
Trial: 2653119
Drug: General anesthesia
RxNorm normalized name: Ethers for general anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General anesthesia (GA) with 0.2 mg.kg‐1 flunitrazepam, 5 micrograms.kg‐1 fentanyl, intubation with 0.08 mg.kg‐1 vecuronium, and ventilation with nitrous oxide and oxygen (50% each). Further injections of 2 micrograms.kg‐1 fentanyl every 30 min.
Trial: 29043911
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose of alcohol
Trial: 6362465
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose of alcohol
Trial: 31466942
Drug: Smartphone-enabled video-observed
RxNorm normalized name: Enablex
DrugBank: Darifenacin (DB00496)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Smartphone-enabled video-observed treatment
Trial: 23934239
Drug: HCG injection
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCG injection before IUI
Trial: 23934239
Drug: HCG injection
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCG injection after IUI
Trial: 9730451
Drug: Intravesical mitomycin
RxNorm normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravesical mitomycin C (MMC) 30 mg, weekly for 4 weeks, then monthly for 5 months
Trial: 9730451
Drug: Intravesical bacille
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical bacille Calmette‐Guérin (BCG), weekly for 6 weeks
Trial: 8381
Drug: Three capsules
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three capsules containing 35 mg of ST-1435 (group A)
Trial: 8381
Drug: Four capsules
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four capsules of ST-1435 (group B)
Trial: 8381
Drug: Five capsules
RxNorm normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five capsules of ST-1435 (group C)
Trial: 29310375
Drug: Topical administration
RxNorm normalized name: Octocaine 5 % Ointment for Oral and Topical Administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical administration of tetracycline ointment every 6 hours for 48 hours postoperatively
Trial: 29310375
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no topical tetracycline)
Trial: 25972817
Drug: Michael's game
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Michael's game (MG)
Trial: 19404945
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of methotrexate, sulfasalazine, and hydroxychloroquine with prednisolone